Ocugen's OCU410 shows 46% lesion growth reduction in GA patients in Phase 2 trial.

Ocugen has reported positive preliminary 12-month data from its Phase 2 ArMaDa clinical trial evaluating OCU410, a gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD). The trial showed a 46% reduction in lesion growth compared to control, with no serious adverse events reported. The global prevalence of dAMD is 266 million, and GA affects approximately 2-3 million people in the U.S. and Europe.